# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Josh Schimmer reiterates ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and maintains $30 pri...
Cantor Fitzgerald analyst Josh Schimmer reiterates ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and maintains $30 pri...
Patients can request a prescription from their existing healthcare provider, or meet with a physician virtually, to request a p...
Neffy, a nasal spray alternative to EpiPen, offers convenience and longer shelf life but faces skepticism from allergists due t...
Marking First New Delivery Method In EU In Over 30 Years
"FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative...